Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset Niemann-Pick Disease, Type C

NDA FilingAdrabetadexNegative

AI Analysis

Summary

Beren Therapeutics announced an FDA extension of the review period for its NDA submission of Adrabetadex for infantile-onset Niemann-Pick Disease, Type C. The extension indicates additional time is needed for regulatory review.

Outcome Details

FDA extended review period for NDA

Importance:6/10

Sentiment:

-0.30

FDANDAreview extensionrare diseasecyclodextrin-based therapy

Read the original article

Published by Drugs.com New Drug Applications on May 28, 2026 10:05 PM

Read Original